Human placenta-derived mesenchymal stem cells transplantation in patients with acute respiratory distress syndrome (ARDS) caused by COVID-19 (phase I clinical trial): safety profile assessment.
Hamid Reza AghayanFatemeh SalimianAtefeh AbediniSamrand Fattah GhaziMasud YunesianSepideh Alavi-MoghadamJalil MakaremKeivan Majidzadeh-AAli HatamkhaniMaryam MoghriAbbas DaneshMohammad Reza Haddad-MarandiHassan SanatiFereshteh AbbasvandiBabak ArjmandPourya AzimiArdeshir GhavamzadehRamin Sarrami ForooshaniPublished in: Stem cell research & therapy (2022)
Iranian Registry of Clinical Trials (IRCT); IRCT20200621047859N4. Registered 1 March 2021, https://en.irct.ir/trial/52947 .
Keyphrases
- acute respiratory distress syndrome
- clinical trial
- phase ii
- extracorporeal membrane oxygenation
- mechanical ventilation
- phase iii
- coronavirus disease
- study protocol
- endothelial cells
- sars cov
- open label
- double blind
- induced pluripotent stem cells
- pluripotent stem cells
- randomized controlled trial
- stem cells
- mesenchymal stem cells
- placebo controlled